Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
3
×
boston top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
3
×
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
novartis
3
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
alder biopharmaceuticals
amgen
bristol-myers squibb
cancer
cell therapy
diagnostics
eli lilly
fremanezumab
immunotherapy
medicare
merck
What
drug
3
×
new
3
×
approval
bio
roundup
advantages
amgen
bar
biogen’s
biopharmaceutical
brings
candidates
class
companies
convo
developed
earlier
expect
failures
fda
gamble
gets
head
littered
market
medco’s
medicines
migraine
mover
nash
news
nod
pain
patients
payers
physicians
plan
preventive
price
pricing
Language
unset
Current search:
drug
×
new
×
" detroit blog main "
×
novartis
×
" boston blog main "
×
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines